Published in Acta Neuropathol on December 10, 2014
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease. Mediators Inflamm (2015) 0.89
Alzheimer's disease: experimental models and reality. Acta Neuropathol (2016) 0.88
How Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend Initiative. Cold Spring Harb Perspect Med (2016) 0.83
The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. Alzheimers Dement (Amst) (2015) 0.82
Hippocampal Injections of Oligomeric Amyloid β-peptide (1-42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway. Front Aging Neurosci (2016) 0.78
Alzheimer disease: modeling an Aβ-centered biological network. Mol Psychiatry (2016) 0.78
Ubiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins. Front Mol Neurosci (2015) 0.77
Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease. Neurobiol Aging (2016) 0.77
Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease. Acta Neuropathol Commun (2016) 0.76
Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. Curr Alzheimer Res (2016) 0.76
Sphingolipid-Enriched Extracellular Vesicles and Alzheimer's Disease: A Decade of Research. J Alzheimers Dis (2016) 0.76
A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. Trends Pharmacol Sci (2017) 0.75
Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein. Aging Cell (2016) 0.75
Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One (2016) 0.75
αT-catenin in restricted brain cell types and its potential connection to autism. J Mol Psychiatry (2016) 0.75
Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain (2017) 0.75
Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease. Neurobiol Aging (2016) 0.75
The Possible Roles of the Dentate Granule Cell's Leptin and Other Ciliary Receptors in Alzheimer's Neuropathology. Cells (2015) 0.75
Human TAU(P301L) overexpression results in TAU hyperphosphorylation without neurofibrillary tangles in adult zebrafish brain. Sci Rep (2017) 0.75
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci (2005) 9.17
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging (1995) 6.86
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Alzheimer's disease. Lancet (2011) 5.35
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci (2001) 5.29
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 4.09
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology (2007) 3.26
Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci (2008) 3.19
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci (2007) 3.10
Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron (2013) 3.09
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2005) 2.97
beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem (2000) 2.96
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
"Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A (1993) 2.91
Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 2.86
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A (2012) 2.84
Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 2.68
Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 2.66
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
Overview on the structure, composition, function, development, and plasticity of hippocampal dendritic spines. Hippocampus (2000) 2.40
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci (2013) 2.26
Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem (1992) 2.26
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci (1998) 2.11
Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04
Three-dimensional analysis of the structure and composition of CA3 branched dendritic spines and their synaptic relationships with mossy fiber boutons in the rat hippocampus. J Comp Neurol (1992) 2.04
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2004) 1.92
Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem (2011) 1.91
Axonally synthesized ATF4 transmits a neurodegenerative signal across brain regions. Cell (2014) 1.89
Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci (2004) 1.88
Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A (1996) 1.87
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci (2011) 1.86
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol (2007) 1.77
Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci (2009) 1.73
scFv antibody: principles and clinical application. Clin Dev Immunol (2012) 1.64
Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A (1991) 1.58
Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol (2014) 1.54
Neuronal activity regulates extracellular tau in vivo. J Exp Med (2014) 1.48
Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron (2014) 1.48
Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem (2000) 1.47
Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One (2011) 1.45
The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron (2013) 1.43
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res (2012) 1.41
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis (2012) 1.39
Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol (2006) 1.38
Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell (2007) 1.37
An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci (2012) 1.36
Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J (2006) 1.32
Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci (2014) 1.28
Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A (2014) 1.28
Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci (2009) 1.27
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A (2007) 1.17
Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem (2013) 1.12
Highly efficient targeted mutagenesis in one-cell mouse embryos mediated by the TALEN and CRISPR/Cas systems. Sci Rep (2014) 1.10
A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines. Hum Mol Genet (2011) 1.10
Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis (2008) 1.03
Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis (2009) 1.02
Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2011) 1.02
Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol Aging (2005) 1.01
Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry (2004) 1.01
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol (2010) 1.01
Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One (2013) 1.00
Why size matters - balancing mitochondrial dynamics in Alzheimer's disease. Trends Neurosci (2013) 1.00
Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem (2013) 1.00
What Renders TAU Toxic. Front Neurol (2013) 1.00
Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu. Neurobiol Aging (2004) 1.00
Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain (2014) 0.94
Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging (1998) 0.94
Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. J Neuropathol Exp Neurol (2001) 0.94
A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One (2013) 0.94
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci (2008) 3.19
Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med (2005) 3.10
Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci U S A (2007) 1.68
Brain area-specific effect of TGF-beta signaling on Wnt-dependent neural stem cell expansion. Cell Stem Cell (2008) 1.67
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A (2008) 1.64
Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem (2005) 1.64
Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron (2012) 1.58
Pronuclear injection for the production of transgenic mice. Nat Protoc (2007) 1.50
Inactivation of TGFbeta signaling in neural crest stem cells leads to multiple defects reminiscent of DiGeorge syndrome. Genes Dev (2005) 1.50
Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One (2011) 1.45
Neural crest stem cell maintenance by combinatorial Wnt and BMP signaling. J Cell Biol (2005) 1.44
Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis (2008) 1.42
Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One (2010) 1.37
Primary support cultures of hippocampal and substantia nigra neurons. Nat Protoc (2009) 1.33
Design of custom-shaped vascularized tissues using microtissue spheroids as minimal building units. Tissue Eng (2006) 1.29
Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol (2003) 1.24
Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A (2010) 1.24
Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) (2008) 1.23
Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2009) 1.23
Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem (2009) 1.21
Wnt/BMP signal integration regulates the balance between proliferation and differentiation of neuroepithelial cells in the dorsal spinal cord. Dev Biol (2006) 1.21
Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci (2008) 1.21
beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem (2003) 1.19
Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? J Neurochem (2006) 1.17
Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol (2010) 1.16
Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal Biochem (2004) 1.15
A decade of tau transgenic animal models and beyond. Brain Pathol (2007) 1.13
Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.12
Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β. J Mol Neurosci (2011) 1.12
Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A (2011) 1.09
Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics (2010) 1.08
MicroRNA networks surrounding APP and amyloid-β metabolism--implications for Alzheimer's disease. Exp Neurol (2011) 1.08
Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol (2012) 1.03
DiGeorge syndrome and pharyngeal apparatus development. Bioessays (2006) 1.02
Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol Dis (2004) 1.02
Lessons from tau-deficient mice. Int J Alzheimers Dis (2012) 1.01
Animal models reveal role for tau phosphorylation in human disease. Biochim Biophys Acta (2009) 1.01
Genomic organisation, chromosomal localisation tissue distribution and developmental regulation of the PR61/B' regulatory subunits of protein phosphatase 2A in mice. J Mol Biol (2004) 1.01
Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. EMBO J (2003) 1.01
Why size matters - balancing mitochondrial dynamics in Alzheimer's disease. Trends Neurosci (2013) 1.00
The translocator protein (18 kDa): central nervous system disease and drug design. J Med Chem (2009) 0.99
Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. PLoS One (2012) 0.97
Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals. Curr Drug Targets (2004) 0.96
Glial cells under physiologic and pathologic conditions. Arch Neurol (2002) 0.96
Diversity, developmental regulation and distribution of murine PR55/B subunits of protein phosphatase 2A. Eur J Neurosci (2002) 0.96
Tissue-transplant fusion and vascularization of myocardial microtissues and macrotissues implanted into chicken embryos and rats. Tissue Eng (2006) 0.95
Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics (2006) 0.95
Insights into mitochondrial dysfunction: aging, amyloid-β, and tau-A deleterious trio. Antioxid Redox Signal (2012) 0.95
Decoding the non-coding RNAs in Alzheimer's disease. Cell Mol Life Sci (2012) 0.95
Brief update on different roles of tau in neurodegeneration. IUBMB Life (2011) 0.94
Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesized proteome. Cell Mol Life Sci (2014) 0.94
Modes of Aβ toxicity in Alzheimer's disease. Cell Mol Life Sci (2011) 0.94
Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett (2008) 0.93
Possibilities for the prevention and treatment of cognitive impairment and dementia. Br J Psychiatry (2007) 0.91
Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity. Alzheimers Res Ther (2011) 0.91
Comparing navigation-based in vivo knee kinematics pre- and postoperatively between a cruciate-retaining and a cruciate-substituting implant. Int Orthop (2013) 0.91
PTL-1 regulates neuronal integrity and lifespan in C. elegans. J Cell Sci (2013) 0.90
Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies? Trends Mol Med (2002) 0.90
Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem Biophys Res Commun (2009) 0.90
Transgenic mice expressing the nucleoprotein of Borna disease virus in either neurons or astrocytes: decreased susceptibility to homotypic infection and disease. J Virol (2004) 0.90
Parkinson's disease: insights from non-traditional model organisms. Prog Neurobiol (2010) 0.89
A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging Cell (2012) 0.89
How it all started: tau and protein phosphatase 2A. J Alzheimers Dis (2013) 0.89
Slow excitotoxicity in Alzheimer's disease. J Alzheimers Dis (2013) 0.89
Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab (2013) 0.89
Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm (Vienna) (2009) 0.89
P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett (2005) 0.89
Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? J Alzheimers Dis (2008) 0.88
Transgenic mice with ocular overexpression of an adrenomedullin receptor reflect human acute angle-closure glaucoma. Clin Sci (Lond) (2008) 0.88
Alzheimer's disease selective vulnerability and modeling in transgenic mice. J Alzheimers Dis (2009) 0.87
Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice. Biochem Biophys Res Commun (2006) 0.87
Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS One (2011) 0.87
Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem (2014) 0.86
Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy? Med J Aust (2006) 0.86
Navigated cup implantation in hip arthroplasty. Acta Orthop (2009) 0.86
An update on the toxicity of Abeta in Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.85
Self-assembly of sensory neurons into ganglia-like microtissues. J Biotechnol (2005) 0.85
Alzheimer's disease, oestrogen and mitochondria: an ambiguous relationship. Mol Neurobiol (2012) 0.84